125 related articles for article (PubMed ID: 35059760)
1. Radiomics-based prognosis classification for high-risk prostate cancer treated with radiotherapy.
Franzese C; Cozzi L; Badalamenti M; Baldaccini D; D'Agostino G; Fogliata A; Navarria P; Franceschini D; Comito T; Clerici E; Reggiori G; Tomatis S; Scorsetti M
Strahlenther Onkol; 2022 Aug; 198(8):710-718. PubMed ID: 35059760
[TBL] [Abstract][Full Text] [Related]
2. Treatment of prostate cancer with radiotherapy: should the entire seminal vesicles be included in the clinical target volume?
Kestin L; Goldstein N; Vicini F; Yan D; Korman H; Martinez A
Int J Radiat Oncol Biol Phys; 2002 Nov; 54(3):686-97. PubMed ID: 12377319
[TBL] [Abstract][Full Text] [Related]
3. Incidence, location, and significance of periprostatic and periseminal vesicle lymph nodes in prostate cancer.
Kothari PS; Scardino PT; Ohori M; Kattan MW; Wheeler TM
Am J Surg Pathol; 2001 Nov; 25(11):1429-32. PubMed ID: 11684961
[TBL] [Abstract][Full Text] [Related]
4. Changes in Magnetic Resonance Imaging Radiomic Features in Response to Androgen Deprivation Therapy in Patients with Intermediate- and High-risk Prostate Cancer.
Tharmalingam H; Tsang YM; Alonzi R; Beasley W; Taylor NJ; McWilliam A; Padhani A; Choudhury A; Hoskin PJ
Clin Oncol (R Coll Radiol); 2022 Jun; 34(6):e246-e253. PubMed ID: 35033410
[TBL] [Abstract][Full Text] [Related]
5. [Changes in target volumes definition by using MRI for prostate bed radiotherapy planning--preliminary results].
Sefrová J; Paluska ; Odrázka K; Belobradek Z; Hoffmann P; Prosvic P; Brod'ák M; Louda M; Macingová Z; Vosmik M
Klin Onkol; 2010; 23(4):256-63. PubMed ID: 20806824
[TBL] [Abstract][Full Text] [Related]
6. Integrating CT-based radiomic model with clinical features improves long-term prognostication in high-risk prostate cancer.
Ching JCF; Lam S; Lam CCH; Lui AOY; Kwong JCK; Lo AYH; Chan JWH; Cai J; Leung WS; Lee SWY
Front Oncol; 2023; 13():1060687. PubMed ID: 37205204
[TBL] [Abstract][Full Text] [Related]
7. Relationship between prostate volume, prostate-specific antigen nadir, and biochemical control.
Kaminski JM; Hanlon AL; Horwitz EM; Pinover WH; Mitra RK; Hanks GE
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(4):888-92. PubMed ID: 11958880
[TBL] [Abstract][Full Text] [Related]
8. Clinical application of high-dose, image-guided intensity-modulated radiotherapy in high-risk prostate cancer.
Bayley A; Rosewall T; Craig T; Bristow R; Chung P; Gospodarowicz M; Ménard C; Milosevic M; Warde P; Catton C
Int J Radiat Oncol Biol Phys; 2010 Jun; 77(2):477-83. PubMed ID: 19733014
[TBL] [Abstract][Full Text] [Related]
9. Treatment simulations with a statistical deformable motion model to evaluate margins for multiple targets in radiotherapy for high-risk prostate cancer.
Thörnqvist S; Hysing LB; Zolnay AG; Söhn M; Hoogeman MS; Muren LP; Bentzen L; Heijmen BJ
Radiother Oncol; 2013 Dec; 109(3):344-9. PubMed ID: 24183863
[TBL] [Abstract][Full Text] [Related]
10. Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer.
Fonteyne V; De Gersem W; De Neve W; Jacobs F; Lumen N; Vandecasteele K; Villeirs G; De Meerleer G
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1013-20. PubMed ID: 19386427
[TBL] [Abstract][Full Text] [Related]
11. Interfractional Seminal Vesicle Motion Relative to the Prostate Gland for Image-guided Radiotherapy for Prostate Cancer with/without Androgen Deprivation Therapy: A Retrospective Cohort Study.
Waki T; Katsui K; Mitsuhashi T; Ogata T; Katayama N; Takemoto M; Nasu Y; Kumon H; Kanazawa S
Acta Med Okayama; 2017 Feb; 71(1):31-39. PubMed ID: 28238008
[TBL] [Abstract][Full Text] [Related]
12. Prostate and seminal vesicle volume based consideration of prostate cancer patients for treatment with 3D-conformal or intensity-modulated radiation therapy.
Reddy NM; Nori D; Chang H; Lange CS; Ravi A
Med Phys; 2010 Jul; 37(7):3791-801. PubMed ID: 20831087
[TBL] [Abstract][Full Text] [Related]
13. Dosimetric implications of residual seminal vesicle motion in fiducial-guided intensity-modulated radiotherapy for prostate cancer.
Stenmark MH; Vineberg K; Ten Haken RK; Hamstra DA; Feng M
Med Dosim; 2012; 37(3):240-4. PubMed ID: 22189029
[TBL] [Abstract][Full Text] [Related]
14. Risk Factors for Biochemical Recurrence After PSMA-PET-Guided Definitive Radiotherapy in Patients With
Spohn SKB; Birkenmaier V; Ruf J; Mix M; Sigle A; Haehl E; Adebahr S; Sprave T; Gkika E; Rühle A; Nicolay NH; Kirste S; Grosu AL; Zamboglou C
Front Oncol; 2022; 12():898774. PubMed ID: 35747822
[TBL] [Abstract][Full Text] [Related]
15. Stage T3b prostate cancer diagnosed by seminal vesicle biopsy and treated with neoadjuvant hormone therapy, permanent brachytherapy and external beam radiotherapy.
Stone NN; Stock RG
BJU Int; 2019 Feb; 123(2):277-283. PubMed ID: 29956864
[TBL] [Abstract][Full Text] [Related]
16. Is androgen deprivation therapy necessary in all intermediate-risk prostate cancer patients treated in the dose escalation era?
Castle KO; Hoffman KE; Levy LB; Lee AK; Choi S; Nguyen QN; Frank SJ; Pugh TJ; McGuire SE; Kuban DA
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):693-9. PubMed ID: 22836052
[TBL] [Abstract][Full Text] [Related]
17. Nomograms for Metastasis-Free and Overall Survival for Pathologically Node Positive Prostate Cancer Patients Treated With or Without Radiation Therapy Plus Short-Term ADT.
Hutten R; Tward JD
Clin Genitourin Cancer; 2022 Jun; 20(3):e263-e269. PubMed ID: 35304077
[TBL] [Abstract][Full Text] [Related]
18. Optimal contouring of seminal vesicle for definitive radiotherapy of localized prostate cancer: comparison between EORTC prostate cancer radiotherapy guideline, RTOG0815 protocol and actual anatomy.
Qi X; Gao XS; Asaumi J; Zhang M; Li HZ; Ma MW; Zhao B; Li FY; Wang D
Radiat Oncol; 2014 Dec; 9():288. PubMed ID: 25526901
[TBL] [Abstract][Full Text] [Related]
19. Introducing a prognostic score for pretherapeutic assessment of seminal vesicle invasion in patients with clinically localized prostate cancer.
Salomon L; Porcher R; Anastasiadis AG; Levrel O; Saint F; De la Taille A; Vordos D; Cicco A; Hoznek A; Chopin D; Abbou CC; Lagrange JL
Radiother Oncol; 2003 Jun; 67(3):313-9. PubMed ID: 12865180
[TBL] [Abstract][Full Text] [Related]
20. Seminal vesicle involvement in patients with D1 disease predicts early prostate specific antigen recurrence and metastasis after radical prostatectomy and early androgen ablation.
Ahlering TE; Skarecky DW; McLaren CE; Weinberg AC
Cancer; 2002 Mar; 94(6):1648-53. PubMed ID: 11920524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
